Traders should monitor the upcoming regulatory update and biomechanical gait data in 2Q 2026, which could validate the neural recovery mechanism of NVG-291. Despite a wider net loss, the improved cash position supports continued development, but future dilution risk remains if additional funding is needed.
Price Chart
Executive Summary
NervGen Pharma reported full-year 2025 financial results and provided clinical updates, including completion of its End-of-Phase 2 meeting with the FDA and plans to initiate a Phase 3 trial in chronic tetraplegia in mid-2026. While R&D expenses decreased, net loss nearly doubled to $44.1 million due to non-cash charges, and cash increased to $22.1 million. The company expects to release additional clinical data in 2Q 2026.
Key Financial Metrics
Key Facts
- Completed End-of-Phase 2 FDA meeting; regulatory update expected in early 2Q 2026
- On track to initiate Phase 3 study in chronic tetraplegia in mid-2026
- Cash and investments increased to $22.1 million as of December 31, 2025, from $17.3 million in 2024
- R&D expenses decreased to $13.9 million in 2025 from $15.8 million in 2024
- Net loss widened to $44.1 million in 2025 from $24.3 million in 2024, driven by $24.8 million in non-cash expenses
- Biomechanical gait data from CONNECT SCI study expected in 2Q 2026
Financial Impact
Net loss increased by 81% YoY to $44.1M, primarily due to non-cash expenses; cash position improved by $4.8M to $22.1M
Risk Factors
- Net loss nearly doubled due to non-cash charges, raising concerns about sustainability
- Clinical timelines are dependent on regulatory feedback and additional funding
- No revenue-generating products; company remains in clinical development stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.50 (+20.27%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.50 (−20.27%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.50 (−25.79%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.50 (−14.83%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.50 (−14.83%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.50 (+29.29%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.50 (+25.05%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.50 (−27.58%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.50 (−27.58%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.50 (+29.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers